Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1

• US 9,173,895 B2
• Filed: 12/15/2010
• Issued: 11/03/2015
• Est. Priority Date: 12/16/2009
• Status: Active Grant

• Current Assignee: CURNA, Inc. (Opko Health, Inc.)
• Original Assignee: CURNA, Inc. (Opko Health, Inc.)
• Inventors: Collard, Joseph, Khorkova Sherman, Olga
• Primary Examiner(s): VIVLEMORE, TRACY ANN
• Application Number:
  US13/516,097
• Publication Number:
  US 20130116300A1
• Time in Patent Office: 1,784 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 15/1137 against enzymes viral enzymes C12N15/1131; receptors C12N15/1138
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/113 targeting other non-coding nucleic acids, e.g. antagomirs
• CPC Class Codes: C12N 2310/313 Phosphorodithioates
• CPC Class Codes: C12N 2310/314 Phosphoramidates
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/322 2'-R Modification
• CPC Class Codes: C12N 2310/3231 : having an additional ring, e.g. LNA, ENA
• CPC Class Codes: C12N 2310/3521 : Methyl
• CPC Class Codes: C12N 2310/3525 : MOE, methoxyethoxy
• CPC Class Codes: C12Y 304/21112 : Site-1 protease (3.4.21.112), i.e. subtilisin kexin isozyme-1
• CPC Class Codes: Y10T 436/143333 : Saccharide [e.g., DNA, etc.]

Abstract

The present invention relates to antisense oligonuclotides that modulate the expression of and/or function of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1), in particular, by targeting natural antisense polynucleotides of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MBTPS1.

Claims

1. A method of upregulating a function of and/or the expression of a Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) poly in patient cells or tissues in vivo or in vitro comprising:

contacting said cells or tissues with at least one antisense oligonucleotide 15 to 30 nucleotides in length wherein said at least one oligonucleotide is specific for and specifically hybridizes to a natural antisense polynucleotide of the MBTPS1 gene and has at least 80% sequence identity to a reverse complement of a polynucleotide comprising 15 to 30 nucleotides within nucleotides 1 to 1240 of SEQ ID NO;

2;

thereby upregulating a function of and/or the expression of the Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide in patient cells or tissues in vivo or in vitro.

11. The method of claim 1, wherein the at least one oligonucleotide comprises at least one oligonucleotide sequences set forth as SEQ ID NOS:

3 to 6.

2. A method of upregulating a function of and/or the expression of a Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide in patient cells or tissues in vivo or in vitro comprising:

contacting said cells or tissues with at least one antisense oligonucleotide 15 to 30 nucleotides in length wherein said at least one oligonucleotide is specific for and specifically hybridizes to a natural antisense polynucleotide of the MBTPS1 gene and has at least 90% sequence identity to a reverse complement of a natural antisense of a Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide;

thereby upregulating a function of and/or the expression of the Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide in patient cells or tissues in vivo or in vitro.

3. A method of upregulating a function of and/or the expression of a Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide in patient cells or tissues in vivo or in vitro comprising:

contacting said cells or tissues with at least one antisense oligonucleotide of 15 to 30 nucleotides in length that specifically targets and specifically hybridizes to a region of a natural antisense polynucleotide of the Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide wherein said natural antisense polynucleotide comprises SEQ ID NO;

2;

thereby upregulating a function of and/or the expression of the Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide in patient cells or tissues in vivo or in vitro.

4. The method of claim 3, wherein a function of and/or the expression of the Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) is increased in vitro or in vitro with respect to a control.

5. The method of claim 3, wherein the at least one antisense oligonucleotide targets a natural antisense polynucleotide antisense to coding nucleic acid sequences of a Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide.

6. The method of claim 3, wherein the at least one antisense oligonucleotide targets a natural antisense polynucleotide having overlapping sequences with a Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide.

7. The method of claim 3, wherein the at least one antisense oligonucleotide comprises one or more modifications selected from:

at least one modified sugar moiety, at least one modified internucleoside linkage, at least one modified nucleotide, and combinations thereof.

8. The method of claim 7, wherein the one or more modifications comprise at least one modified sugar moiety selected from:

a 2′

-O-methoxyethyl modified sugar moiety, a 2′

-methoxy modified sugar moiety, a 2′

-O-alkyl modified sugar moiety, a bicyclic sugar moiety, and combinations thereof.

9. The method of claim 7, wherein the one or more modifications comprise at least one modified, internucleoside linkage selected from:

as phosphorothioate, alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.

10. The method of claim 7, wherein the one or more modifications comprise at least one modified nucleotide selected from:

a peptide nucleic acid (PNA), a locked nucleic acid (LNA), an arabino-nucleic acid (FANA), an analogue, a derivative, and combinations thereof.

12. A method of upregulating a function of and/or the expression of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) in mammalian cells or tissues in vivo or in vitro comprising:

contacting said cells or tissues with at least one antisense oligonucleotide of about 15 to 30 nucleotides in length specific for and that specifically hybridizes to a natural antisense strand of a Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide wherein said at least one antisense oligonucleotide has at least 80% identity to 15-30 nucleotides of at least one nucleic acid sequence set forth as SEQ ID NO;

1 or an RNA polynucleotide transcribed from the MBTPS1 gene; and

, upregulating the function and/or expression of the Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) in mammalian cells or tissues in vivo or in vitro.

13. A method of preventing or treating a disease associated with at least one Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide and/or at least one encoded product thereof, comprising:

administering to a patient a therapeutically effective dose of at least one antisense oligonucleotide of 15 to 30 nucleotides in length that specifically hybridizes to a natural antisense polynucleotide of said at least one Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide wherein said natural antisense polynucleotide comprises SEQ ID NO;

2 and upregulates expression of said at least one Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide;

thereby preventing or treating the disease associated with the at least one Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide and/or at least one encoded product thereof.

14. The method of claim 13, wherein a disease associated with the at least one Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide is selected from:

a disease or disorder associated with ER stress response, an inflammatory bowel disease, metabolic disease or disorder, a lipid metabolism disease or disorder, a disease or disorder associated with impaired functioning of Sterol regulator element-binding proteins (SREBPs), a cardiovascular disease or disorder, a hemorrhagic fever, a hepatic disease or disorder, an endochondral bone development disease or disorder.

15. The method according to claim 14 wherein the diseases or disorders are selected from the group consisting of Colitis, obesity, diabetes, hypercholesterolemia, dyslipidemia, Crimean-congo hemorrhagic fever, chondrodysplasia, chondrocyte apoptosis or disorganized collagen network.